首页> 外文期刊>American Journal of Cancer Research >The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target
【24h】

The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target

机译:组蛋白甲基转移酶DOT1L:调节功能和癌症治疗目标

获取原文
           

摘要

DOT1L is a unique histone methyltransferase that targets the histone H3 lysine 79 (H3K79) residue for mono-, di- and tri- methylation. Histone H3K79 mono- and di-methylation results in active gene transcription, while H3K79 tri-methylation is associated with gene repression. DOT1L has a critical role in regulating gene transcription, development, cell cycle progression, somatic reprogramming and DNA damage repair. DOT1L interacts with Mixed Lineage Leukemia (MLL) fusion proteins, leading to enhanced H3K79 methylation, maintenance of open chromatin, overexpression of downstream oncogenes and leukemogenesis. Importantly, small molecule DOT1L inhibitors have been recently developed, and one of the DOT1L inhibitors is already under investigation in a Phase I clinical trial in patients with MLL fusion gene-driven leukemia.
机译:DOT1L是独特的组蛋白甲基转移酶,可靶向组蛋白H3赖氨酸79(H3K79)残基,以实现单,二和三甲基化。组蛋白H3K79单甲基化和二甲基化导致活跃的基因转录,而H3K79三甲基化与基因阻抑有关。 DOT1L在调节基因转录,发育,细胞周期进程,体细胞重编程和DNA损伤修复中起关键作用。 DOT1L与混合谱系白血病(MLL)融合蛋白相互作用,导致增强的H3K79甲基化,维持开放的染色质,下游癌基因的过表达和白血病的发生。重要的是,最近已经开发了小分子DOT1L抑制剂,其中一种DOT1L抑制剂已经在I期临床试验中针对MLL融合基因驱动的白血病患者进行了研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号